USPTO serial 79380466
NORTHX BIOLOGICS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 5, 2025
- Examiner
- REID, CAILE MAUREEN
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with NORTHX BIOLOGICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Alexander Lazouski
Alexander Lazouski Lazouski IP LLC14726 Bowfin Terrace, Suite 1Lakewood Ranch, FL 34202United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals used in industry and science, especially proteins, enzymes and modifications thereof | ACTIVE | — |
| 005 | Diagnostic preparations for pharmaceutical purposes; a full line of medicinal products; biological preparations for medical purposes; chemical preparations for medical purposes; diagnostic preparations for medical purposes; biological reagents for medical use; somatic cell therapy products, namely, muscle cells, blood cells, skin cells and nerve cells for medical use; pharmaceutical preparations for gene therapy use, namely, virus, viral vector, and plasmid DNA material to be used in gene therapy applications for medical purposes; cell-based preparations, namely, plasmid DNA and mRNA cell therapy for medical purposes; nucleic acid preparations being nucleic acid sequences for medical purposes; vaccines; recombinant proteins arrays for medical diagnosis purposes; therapeutic antibodies for medical purposes; microbial expressed protein arrays for medical diagnosis purposes; DNA vaccines; DNA plasmids being vaccines and pharmaceutical preparations for use in gene therapies | ACTIVE | — |
| 009 | Scientific apparatus and instruments being medical laboratory research instruments for controlling, measuring, accelerating, and transporting chemicals for use in biochemical and genetic research; Scientific apparatus and instruments, namely, apparatus and instruments being medical laboratory research instruments for use in gene therapy, plasmid DNA production, cell banking and DNA sequencing | ACTIVE | — |
| 042 | Product research and development; new product analytical development; research and development in the pharmaceutical and biotechnology fields; research and development in the field of microorganisms and cells; research and development for the pharmaceutical industry; biochemical research and development; research services for the development of new pharmaceutical products and advanced therapy product processes; research and development of vaccines and medicines; research and development in the field of diagnostic preparations; development of new products being biological drugs and advanced therapy product processes; medical research laboratory services; research on the subject of pharmaceuticals; provision of information and data relating to medical preparation research and development; scientific research services, and technology advisory services related to pharmaceutical research and development, development of gene therapy products, and genetic biologic products; product research and development in the field of cell banking; product research and development in the field of plasmid DNA production; product research and development in the field of DNA sequencing; medical and scientific research, namely, conducting clinical trials for others; medical and scientific research, namely, conducting clinical trials for others for pharmaceutical products; scientific and medical research on cell banks. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by NorthX Biologics AB
- Other trademarks owned by NorthX Biologics AB
- Other trademarks owned by NorthX Biologics AB
- Other trademarks owned by NorthX Biologics Matfors AB
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 042
- Similar marks named NORTHX BIOLOGICS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 5, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 13, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Feb 13, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Dec 11, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Nov 27, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Nov 26, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 26, 2025 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Nov 26, 2025 | EWOR | TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED | — |
| Nov 26, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 26, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 26, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Nov 26, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Nov 5, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 5, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 5, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 17, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 17, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 11, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 14, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 13, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 13, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 13, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 24, 2025 | GEAN | NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED | — |
| Apr 24, 2025 | GEAP | EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED | — |
| Apr 24, 2025 | EPEN | COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY | — |
| Apr 24, 2025 | CPEA | EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED | — |
| Mar 27, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 27, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 27, 2025 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Mar 22, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Mar 4, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 4, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Oct 7, 2024 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Oct 7, 2024 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 7, 2024 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Aug 20, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 20, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 20, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 2, 2024 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| May 22, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Apr 28, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Apr 28, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Apr 17, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Apr 16, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 15, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 21, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 21, 2023 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Nov 21, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 21, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 21, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Nov 21, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Oct 10, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 6, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 5, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |